复可托治疗儿童哮喘合并反复呼吸道感染的疗效观察

Effect of spleen aminopeptide on asthmatic children with recurrent respiratory infection

目的研究复可托对儿童哮喘合并反复呼吸道感染的临床疗效。方法采用随机法将收住院的296名哮喘合并反复呼吸道感染患儿分为治疗组149例及对照组147例。两组均行吸入糖皮质激素(ICS)的基础治疗,或联合应用β受体激动剂(LABA)、白三烯受体拮抗剂(LTA)或者氨茶碱治疗,在此基础上治疗组加用复可托治疗,观察两组治疗后患儿哮喘及感染症状改善情况并对治疗前及治疗后患儿T细胞亚群的变化进行对比分析。结果治疗组在哮喘及呼吸道感染次数上明显少于对照组(P<0.05),在咳嗽、喘息及发热方面的改善程度也明显优于对照组(P<0.05)。治疗6个月后治疗组CD+3、CD+4及CD+8较治疗前均有提高(P<0.05),且与对照组相比其T细胞亚群变化程度更为明显。两组患者的不良反应发生率差异无统计学意义。(P>0.05)。结论哮喘合并反复呼吸道感染的患儿使用复可托治疗后能有效改善哮喘及感染症状,疗效显著,安全性高,可在临床推广应用。

Objective To study the efficacy of spleen aminopeptide on children with bronchial asthma complicated hyrecurrent respiratory infection. Methods 296 asthmatic children with recurrent respiratory infection were randomly divided into observation group （149 cases） and control group （147 cases）. The observation group accepted spleen amin- opeptide and the control group accepted placebo at the same frequency. The severity of asthma and recurrent respiratory infection, T lymphocyte subgroup ratio were investigated. Results The number of asthma and respiratory tract infections in the observation group were significantly less than that of the control group （P〈0. 05）, The coughing, wheezing, and fever aspects of the degree of improvement in the observation group were significantly better than that of the control group （P〈0.05）. After 6 months of treatment, the CD＋ ,CD＋ and CD＋ of the observation group were all increased than before treatment （P〈0.05）. Their degree of change in T cell subsets in the observation group was more obvious than that in the control group. Adverse reactions of the two groups were not statistically significant difference （P〉0.05）. Conclusion It will be feasible that spleen aminopeptidecan be used to treat children with bronchial asthma complicated by recurrent respiratory infection.